Simplifying HIV Treatment in the Presence of Drug Resistance; Preventing from the Start : Episode 10

Addressing Suboptimal Treatment Response in HIV

June 14, 2024

By Paul E. Sax, MD
Shauna Applin, ARNP

Opinion

Video

A panel of experts on HIV discuss decision-making practices for patients who have suboptimal response to their current treatment regimen.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP: 1.The Role of the Primary Care Provider/Advanced Practice Provider in HIV Management

EP: 2.Evolving Treatment Practices and Guidelines for HIV

EP: 3.Key Clinical Considerations in HIV Treatment Decisions

EP: 4.HIV Treatment: Discussing Adverse Events with Patients

EP: 5.Importance of Starting HIV Treatment Early

EP: 6.Treatment Resistance in HIV

EP: 7.HIV Drug Resistance Testing Practices and Patient Education

EP: 8.Managing Suboptimal Adherence to HIV Medications

EP: 9.HIV Treatment Clinical Experiences

EP: 10.Addressing Suboptimal Treatment Response in HIV

EP: 11.Current HIV Treatment Regimens

EP: 12.Rapid Treatment Initiation in HIV

EP: 13.Switching Therapies for Patients with HIV and History of Resistance

EP: 14.Resources Available for Patients with HIV Drug Resistance

EP: 15.Factors that Inform Treatment Selection in HIV

EP: 16.Switching Therapies in HIV

EP: 17.Restarting Therapy in Patients with HIV

EP: 18.Treatment Guidelines and Regimens for Managing Patients with HIV

EP: 19.Differences in Binding Affinity Between Integrase Inhibitors in HIV

EP: 20.Head-to-Head Comparisons on B/F/TAF Compared With Other HIV Regimens

EP: 21.Recent Studies on HIV Treatments and Patient-Reported Outcomes

EP: 22.HIV: Treating Patients with Viral Mutations

BIC = bictegravir

DRV = darunavir

DTG = dolutegravir

F/TAF = FTC/TAF = Emtricitabine/Tenofovir alafenamide

F/TDF = FTC/TDF = Emtricitabine/Tenofovir disoproxil fumarate

B/F/TAF = BIC/FTC/TAF = Bictegravir/Emtricitabine/Tenofovir alafenamide (single tablet regimen)

DTG/ABC/3TC = Dolutegravir/Abacavir/Lamivudine (single tablet regimen)

DTG + F/TAF = DTG + FTC/TAF = Dolutegravir + Emtricitabine/Tenofovir alafenamide (multi-tablet regimen)

D/C/F/TAF = DRV/COBI/FTC/TAF = Darunavir/Cobicistat/Emtricitabine/Tenofovir alafenamide (single tablet regimen)

DTG/3TC = Dolutegravir/Lamivudine (single tablet regimen)

CAB = Cabotegravir

CAB + RPV = Cabotegravir + Rilpivirine

Video content above is prompted by the following question:

How do you manage a patient with HIV who has a suboptimal response to their current treatment regimen?

Newsletter

Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.

Recent Videos

Expanding HIV Prevention: Overcoming Barriers and Embracing Long-Acting PrEP

Expanding HIV Prevention: Overcoming Barriers and Embracing Long-Acting PrEP

National Youth HIV/AIDS Awareness Day Reminds Young People They Are Not Forgotten

National Youth HIV/AIDS Awareness Day Reminds Young People They Are Not Forgotten

The Importance to Address and Help Visceral Adiposity in HIV Patients

The Importance to Address and Help Visceral Adiposity in HIV Patients

Clinical Insights on HIV-Associated Visceral Fat Following FDA Approval of Tesamorelin F8

Clinical Insights on HIV-Associated Visceral Fat Following FDA Approval of Tesamorelin F8

Phase II Study Shows Efficacy of 6-Month Regimen of Lenacapavir, Teropavimab, and Zinlirvimab for HIV

Phase II Study Shows Efficacy of 6-Month Regimen of Lenacapavir, Teropavimab, and Zinlirvimab for HIV

ALLIANCE Study: B/F/TAF Achieves Sustained HIV and HBV Suppression

ALLIANCE Study: B/F/TAF Achieves Sustained HIV and HBV Suppression

Immunocore Reports Some PWH Achieve Viral Control and Dose-Dependent Active HIV Reservoir Reduction in IMC-M113V Trial

Immunocore Reports Some PWH Achieve Viral Control and Dose-Dependent Active HIV Reservoir Reduction in IMC-M113V Trial

ViiV Healthcare Presents Potential Long-Acting HIV Therapies

ViiV Healthcare Presents Potential Long-Acting HIV Therapies

The Business Sector's Advocacy to Maintain Funding for HIV Prevention, Research, Treatment

The Business Sector's Advocacy to Maintain Funding for HIV Prevention, Research, Treatment

Apretude PrEP Shows High Efficacy, Safety in Diverse Studies

Apretude PrEP Shows High Efficacy, Safety in Diverse Studies

Related Content

|

|

Simplifying HIV Treatment in the Presence of Drug Resistance; Preventing from the Start

Contagion, Spring 2025 Digital Edition

Do Not Sell My Information

Terms & Conditions

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2025 MJH Life Sciences

All rights reserved.